D. Lindquist

发表

Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer.

A. Buzdar, D. Finkelstein, P. Goss, 2015, European journal of cancer.

Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial.

W. Gradishar, A. Buzdar, D. Finkelstein, 2013, The Lancet. Oncology.

Results of a phase II multicenter trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer.

D. Garfield, M. Neubauer, L. Asmar, 2005, Lung cancer.

Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy

J. Sparano, C. Vogel, N. Iannotti, 2013, Breast Cancer Research and Treatment.

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

M. Casey, S. Stein, C. Geyer, 2008, Breast Cancer Research and Treatment.

Lorlatinib Salvages CNS Relapse in an ALK‐Positive Non–Small‐Cell Lung Cancer Patient Previously Treated With Crizotinib and High‐Dose Brigatinib

R. Camidge, Justin M Honce, D. Lindquist, 2019, Clinical lung cancer.

Local Recurrence in T1-2 Breast Cancer

T. Tot, D. Hellberg, D. Lindquist, 2011 .

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

M. Berger, S. Stein, C. Geyer, 2006, The New England journal of medicine.

Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer.

J. Hainsworth, N. Robert, N. Senzer, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of a Phase II study of weekly docetaxel and carboplatin in Stage IIIB (with effusion) or Stage IV non-small cell lung cancer patients age

L. Asmar, J. Sandbach, C. Weissman, 2006, Lung cancer.

Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study.

N. Robert, F. Holmes, J. O’Shaughnessy, 2013, The Lancet. Oncology.

Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients

J. O’Shaughnessy, J. Goldschmidt, J. Blum, 2019, npj Breast Cancer.

Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients

J. O’Shaughnessy, J. Goldschmidt, J. Blum, 2019, npj Breast Cancer.

Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial

G. Hortobagyi, D. Cameron, L. Hart, 2017, Breast Cancer Research and Treatment.

Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy

W. Gradishar, A. Buzdar, K. Strasser-Weippl, 2015, Breast Cancer Research.

Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine

H. Koeppen, F. Holmes, J. O’Shaughnessy, 2015, Clinical Cancer Research.

Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy.

W. Gradishar, A. Buzdar, K. Strasser-Weippl, 2016, European journal of cancer.

Dual HER2 Suppression with Lapatinib plus Trastuzumab for Metastatic Inflammatory Breast Cancer: A Case Report of Prolonged Stable Disease

Lauren Ogawa, D. Lindquist, 2018, Case Reports in Oncology.